Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 9.35% is 49% below its 5-year average of 18.49%, near the low end of its 5-year range (9.09%–31034.98%).
As of the fiscal period ended Tuesday, June 30, 2026. 99.85% below its 12-month average of 6228.64%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.35%.
DEBT TO ASSETS RATIO
9.35%
DEBT TO ASSETS RATIO AVG TTM
6228.64%
DEBT TO ASSETS RATIO AVG 3Y
3472.13%
DEBT TO ASSETS RATIO AVG 5Y
18.49%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-99.85%
CURRENT VS 3Y AVG
-99.73%
CURRENT VS 5Y AVG
-49.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+10287.62%
vs the sector median at left
20/20 Biolabs Inc.
Market Cap
$4.32M
Debt to Assets Ratio
9.35%
TTM Avg
6228.64%
3Y Avg
3472.13%
5Y Avg
18.49%
Market Cap
$4.40M
Debt to Assets Ratio
0.37%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.21M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.53M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.55M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.93M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.32M | 9.35% | 6228.64% | 3472.13% | 18.49% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.40M | 0.37% | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | 0.00% | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | 0.00% | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.53M | 0.00% | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | 0.00% | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.69M | 0.00% | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $4.71M | 0.52% | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | 0.29% | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | 0.00% | N/A | N/A | N/A |
Debt/Assets
9.3%
Debt/Equity
0.18
Current Ratio
1.99
Interest Coverage
-21.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 9.35% |
| 2026-03-31 | 15.95% |
| 2025-12-31 | 31034.98% |
| 2025-09-30 | 52.35% |
| 2025-06-30 | 30.58% |
| 2024-12-31 | 41.89% |
| 2023-12-31 | 19.36% |
| 2023-09-30 | 19.36% |
| 2023-06-30 | 25.33% |
| 2023-03-31 | 21.64% |
| 2022-12-31 | 11.55% |
| 2022-09-30 | 11.55% |
| 2022-06-30 | 9.09% |
| 2021-12-31 | 12.40% |
| 2021-09-30 | 12.40% |
